On Friday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was 2.99% up from the session before settling in for the closing price of $36.17. A 52-week range for NAMS has been $14.06 – $42.00.
When this article was written, the company’s average yearly earnings per share was at 42.13%. With a float of $80.55 million, this company’s outstanding shares have now reached $113.17 million.
NewAmsterdam Pharma Company NV (NAMS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward NewAmsterdam Pharma Company NV stocks. The insider ownership of NewAmsterdam Pharma Company NV is 29.16%, while institutional ownership is 67.15%. The most recent insider transaction that took place on Dec 02 ’25, was worth 10,250,554. Before that another transaction happened on Dec 02 ’25, when Company’s Former Affiliate proposed sale 4,500,000 for $38.33, making the entire transaction worth $172,485,000.
NewAmsterdam Pharma Company NV (NAMS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.9 earnings per share (EPS) during the time that was less than consensus figure (set at -0.47) by -0.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.13% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
You can see what NewAmsterdam Pharma Company NV (NAMS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.57. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 119.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.70 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.09 million. That was better than the volume of 0.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 28.53%.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 77.23%, which indicates a significant increase from 36.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.76 in the past 14 days, which was lower than the 1.83 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.97, while its 200-day Moving Average is $25.38. However, in the short run, NewAmsterdam Pharma Company NV’s stock first resistance to watch stands at $37.75. Second resistance stands at $38.25. The third major resistance level sits at $39.25. If the price goes on to break the first support level at $36.25, it is likely to go to the next support level at $35.25. The third support level lies at $34.75 if the price breaches the second support level.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
There are 113,391K outstanding shares of the company, which has a market capitalization of 4.22 billion. As of now, sales total 45,560 K while income totals -241,600 K. Its latest quarter income was 350 K while its last quarter net income were -72,010 K.
